Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Virgin Money London Marathon using Restrata technology to help keep elite athletes COVID-Safe

Restrata

As the Virgin Money London Marathon returns to the city’s streets this Sunday, Restrata, a global contact tracing specialist, will be helping to keep the elite runners COVID-Safe with their cutting-edge technology. Already adopted by businesses and venues, as well as being used at international sporting tournaments, Restrata Platform is now being used to help ensure the world’s top marathoners arrive at the starting line in Greenwich for the 41 st London Marathon. In addition to daily Covid testing, the 100 elite athletes scheduled to take part in the Virgin Money London Marathon, including defending champion and world record holder, Brigid Kosgei, as well as their support staff, are wearing a Restrata tag in the elite hotel. This device means that if a positive case of Covid is recorded, it’s fast and simple to identify who else has shared the same space, at the same time, so that the necessary safety measures can be put in place to prevent any spread of the virus. Restrata Platform was initially designed to protect workers in the energy and industrial sector and ensure their safety. Having been further developed and successfully implemented at cricket tournaments for the Pakistan Super League (PSL), Indian Premier League (IPL) and the English Cricket Board (ECB), Restrata is proud to be part of bringing back large-scale sporting events in a safe, controlled way. Botan Osman, CEO, Restrata, comments: “Supporting the Virgin Money London Marathon this year is incredibly exciting for Restrata. As an international business much of our work is carried out overseas, so with the final stage of the race just a short sprint from our London office, and being a Londoner myself, this project is close to our hearts. “Helping to keep the elite team and their support staff safe with Restrata Platform and our contact tracing technology will ensure that the runners enter the race in top form and with 100% confidence. We're delighted to be able to support Hugh Brasher and his team in staging such a prestigious sporting event.” Hugh Brasher, Event Director of London Marathon Events, adds: “London Marathon Events is delighted to be working with Restrata to ensure we have accurate data to keep our elite athletes safe and healthy as they prepare for the Virgin Money London Marathon. “In this uncertain world, the Restrata technology gives us certainty in planning for some incredible racing between our elite athletes and para-athletes on Sunday 3 October at the 41st London Marathon.” About Restrata Founded in 2006, Restrata has been a pioneer in smart tech solutions that help multi-nationals safeguard their people, strategic assets, and physical infrastructure in some of the most challenging operating environments in the world. Restrata Platform is an integrated safety, security, and mobility cloud-based software. It is designed to manage the safety of people across sites, offices, and countries around the globe. In response to the pandemic, Restrata developed a COVID-Safe module within the Platform, creating a technology-enabled bio-secure environment for the safe return to operations in any industry. The Restrata Platform is already operational across offices, companies, venues, and international tournaments around the world. And in our uncertain world, The Restrata Platform can flex to address most safety and security concerns, leaving you and your workforce as protected and resilient as possible. restrata.com About the London Marathon The London Marathon was first held on 29 March 1981 and the millionth finisher in the history of the event crossed the line in 2016. The 40th Race took place on Sunday 4 October 2020 with elite races on a biosecure closed-loop circuit around St James's Park and 37,966 runners around the world running the virtual Virgin Money London Marathon on the course of their choice any time from 00:00:00 to 23:59:59 BST. Participants were able to download the Virgin Money London Marathon app powered by TCS to record their run. All finishers received a New Balance finisher's t-shirt and medal. In 2019 the Virgin Money London Marathon raised £66.4 million for charity, setting a new Guinness World Record for an annual one-day charity fundraising event for a 13th successive year. This brought the total raised for charity since 1981 to more than £1 billion. London Marathon Events gifts its surplus each year to The London Marathon Charitable Trust. Since 1981, The London Marathon Charitable Trust has awarded grants totalling in excess of £93 million to more than 1,490 projects in London and across the UK. Contact Details Fox Agency Chloe Murray +44 7961 116568 chloe@fox.agency Company Website https://www.restrata.com

October 01, 2021 05:47 AM Eastern Daylight Time

Image

What You Need to Know About Medicare Annual Enrollment

YourUpdateTV

Medicare’s Annual Enrollment Period is almost here — the time (Oct. 15 to Dec. 7) when people can select or make changes to their Medicare coverage for the year ahead. Recently, Rick Dunlop, Health Plan CEO at UnitedHealthcare Medicare & Retirement, participated in a nationwide satellite media tour to discuss tips and resources on finding the right plan. A video accompanying this announcement is available at: https://youtu.be/TDXd22jLN2k The need for clear information on Medicare is great and growing as more than 10,000 Americans turn 65 each day. It is estimated that by 2030, more than 80 million Americans will be eligible for Medicare. People should be aware of their options and what different Medicare plans can offer. With Medicare, it's always a good idea to understand the basics first. Learn about the different parts of Medicare—Medicare Part A, Part B, Part C and Part D—how your Initial Enrollment Period works, the different Medicare coverage options, and how to enroll. There are several options when it comes to Medicare and choosing coverage. You can get Medicare Part A and Part B benefits, either through Original Medicare or a Medicare Advantage plan, but you have other choices to consider too. You may need Part D prescription drug coverage if you take medications regularly. You may decide you want the ease of an all-in-one plan that may also offer extra benefits like dental, vision and fitness, and look to get a Medicare Advantage plan. Or, you may consider a Medicare supplement insurance (Medigap) plan to help with out-of-pocket costs not paid by Original Medicare. For more information, visit gettoknowmedicare.com About Rick Dunlop: Rick Dunlop is a Health Plan CEO with UnitedHealthcare Medicare & Retirement, the largest business dedicated to serving the health and well-being needs of seniors and other Medicare beneficiaries. More people choose UnitedHealthcare for their Medicare coverage than any other insurer. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 30, 2021 07:00 PM Eastern Daylight Time

Video

Hong Kong Baptist University invents novel cell sensor for rapid and low-cost screening of drug-resistant bacteria

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 29 September 2021 - A research team led by scientists at Hong Kong Baptist University (HKBU) has developed a novel cell sensor with a barcode-like micro-channel structure that enables rapid and low-cost screening of drug-resistant bacteria. The invention could potentially be used on a large-scale in resource-limited situations such as frequent safety screenings of water, food and public facilities, as well as urgent surveys of massive samples during an infectious disease outbreak, particularly in developing countries. A research paper on the novel invention was published in the international academic journal Biosensors and Bioelectronics. A research team led by Dr Ren Kangning, Associate Professor of the Department of Chemistry at HKBU (left), designed a fully automatic, microscope-free antimicrobial susceptibility testing (AST) system. It enables rapid and low-cost screening of drug-resistant bacteria by scanning the "barcode" on the cell sensor with a mobile app, which is shown by Chan Chiu-wing, a member of the research team and a PhD student of the Department of Chemistry at HKBU (right). The cell sensor with a barcode-like micro-channel structure comprises two main parts: a cell culture zone and a "barcode" cell sensor. A rapid and low-cost testing approach Antibiotics are often used to treat bacterial infections, but the overuse and misuse of antibiotics have created the problem of drug resistance. Antimicrobial susceptibility testing (AST) is used to determine which antibiotics can effectively inhibit the growth of a certain type of bacteria effectively. However, conventional AST methods are too slow, as they require 16 to 24 hours for results, while modern rapid ASTs are expensive and require elaborated laboratory equipment. A rapid and cost-effective strategy is therefore needed to screen bacterial samples onsite, with advanced laboratory testing arranged only for those suspected of containing drug-resistant bacteria. In response to this need, a research team led by Dr Ren Kangning, Associate Professor of the Department of Chemistry at HKBU designed a fully automatic, microscope-free AST system. It comprises two main parts: a cell culture zone and a "barcode" cell sensor. The cell culture zone consists of a set of micro-channels filled with fluids that contain cell culture media as well as different concentrations of the antibiotic. The "barcode" cell sensor contains an array of "adaptive linear filters" arranged in parallel that resembles a "barcode" structure. Users can finish the onsite screening within three hours by scanning the "barcode" with a mobile app developed by the researchers, and it will indicate whether any drug-resistant pathogenic bacteria is present in the sample. Quantity of bacteria represented by bar length When conducting AST with the system, bacterial samples will be injected into and incubated in the cell culture zone. Bacteria in the test sample inside the micro-channels show different proliferation rates depending on different concentrations of the antibiotic. After completion of the culture period, the bacterial cells will flow through the "adaptive linear filters". The cells will not accumulate around the nanopores on the sidewalls of the micro-channels, instead they will be driven down by the fluid and be collected from the end of the micro-channels. The accumulated cells will then form visible vertical bars, the lengths of which are proportional to the quantity of bacteria cells cultured under the different concentrations of the antibiotic. A cell phone equipped with a macro-lens can then be used to photograph the "barcode" created by the AST. The image will be analysed automatically by the mobile app. Results consistent with conventional AST After the culture period, if all the "bars" of the cell sensor have similar lengths, it means the tested antibiotic cannot inhibit the growth of the bacteria, and thus the bacterial sample is resistant to the tested antibiotic. If the length of the "bars" is in general inversely proportional to the concentration of the antibiotic in the micro-channels, it shows that the tested antibiotic is generally effective at prohibiting the growth of the bacteria, and thus the bacteria is not drug-resistant. When two adjacent "bars" show a sharp difference in terms of length, it indicates that the antimicrobial effect of the antibiotic leaps when its concentration reaches a particular level. The research team tested E. coli and S. aureus with the "barcode" cell sensor and the results were consistent with those of the conventional AST. The test can be completed in three hours, which is much faster than the conventional AST. Microfluidic approaches developed by other researchers can also attain comparable speed, but they rely on expensive instruments for analysis in general. Potential for use in resource-limited regions "Our 'barcode' testing system is a promising new tool in the fight against antimicrobial resistance. We hope that it will benefit the routine screening of drug-resistant bacteria in the food industry, public areas and healthcare facilities as it does not require advanced clinical facilities or professional testing skills," said Dr Ren. The "barcode" cell sensor has a low production cost, and it is estimated to be below one US dollar per piece. The research team has filed a patent application for the "barcode" cell sensor. "We plan to develop our invention into a portable AST instrument, and ultimately, we hope it can be used in resource-limited regions," Dr Ren added. Apart from researchers from HKBU's Department of Chemistry, the research team of the "barcode" cell sensor also included scientists from the Department of Computer Science at HKBU and the School of Medicine at Stanford University. #HongKongBaptistUniversity #HKBU Contact Details Communication and Public Relations Office, HKBU Winnie Shum +852 3411 5262 winnieshum@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

September 29, 2021 09:00 AM Eastern Daylight Time

Image

Agile Therapeutics Partners with Carli Lloyd, U.S. Women’s Soccer Star and Four-Time Olympian, to Bring Awareness to Women’s Health Topics

Agile Therapeutics

Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, announced today a partnership with U.S. Women’s Soccer legend, Carli Lloyd. The partnership with Agile will focus on bringing awareness to women’s health topics, and Agile’s commitment to elevating women’s healthcare. Lloyd, who will play her final game for the U.S. Women’s National Team on October 26 th against South Korea, was attracted to the company’s mission of addressing the healthcare needs of today’s women. “I’m excited to be partnering with a company solely dedicated to women’s health,” said Lloyd. “I aim to work with organizations that focus on things I care about, and staying healthy has been a priority for my career on the field and will continue to be so as I look ahead to my next chapter. Agile’s focus on bringing women options and knowledge when it comes to their healthcare decisions is a mission I’m proud to be part of. And the fact that I’m a Jersey girl, representing a New Jersey company makes it even better.” Agile has built its brand around a commitment to addressing women’s health needs. It received approval from the U.S. Food and Drug Administration (FDA) in February 2020 for its first product, Twirla ® (levonorgestrel and ethinyl estradiol) transdermal system, a weekly contraceptive patch. It currently has four additional contraceptive products in its pipeline. “Carli’s ‘ always believe and never quit ’ attitude fits what Agile Therapeutics believes as a company,” said Al Altomari, CEO of Agile Therapeutics. “We’ve been selective about aligning with the right partners at the right time, and Carli is someone who seamlessly fits our corporate culture, aligns with our values, and understands the importance of empowering women, especially young women, to reach beyond their limits, believe in themselves, and never compromise, especially with their healthcare.” As a growing company, Agile sees this partnership as an opportunity to help further develop its culture and corporate brand by partnering with leaders who share the company’s values and mission.. “Our short-term goal is to establish Twirla in the contraceptive market, and our long-term mission remains the same: Build a robust women’s health franchise, and Carli is a critical piece of that puzzle,” said Altomari. “She’s been a vocal advocate for women, and her voice is an important one in the national conversation about women’s health and healthcare needs. We want to be sure we communicate our message and commitment to women’s health in an authentic and relatable way. This is a mission we share with Carli, and we are proud to welcome her to our team.” About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website. About Twirla® Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Healthcare providers (HCPs) are encouraged to consider Twirla’s reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m2. Twirla is contraindicated in women over 35 years old who smoke. Cigarette smoking increases the risk of serious cardiovascular events from CHC use. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch. Contact Details Matt Riley, Head of Investor Relations and Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com

September 28, 2021 02:52 PM Eastern Daylight Time

BreatheSuite Receives FDA Clearance for Over-the-Counter Device to Turn Regular Metered-Dose Inhalers into Smart Inhalers

BreatheSuite

BreatheSuite Inc., a Canadian connected respiratory health company, today announced that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) for its BreatheSuite Metered-Dose Inhaler (MDI) V1 device. Approved for both prescription and over-the-counter use, the BreatheSuite device turns existing MDIs into smart inhalers by automatically and objectively monitoring and providing feedback on inhaler adherence and technique for people with asthma and COPD. Tens of millions of Americans currently use MDIs. Techniques such as shaking the MDI 10-15 times, as well as breath timing and positioning, can greatly impact the amount of medication that reaches the lungs. For every 100 people who use an inhaler, 90 are using it incorrectly; 66 are not adherent to the medication as prescribed (skipping doses, etc.). Inhaler misuse makes up about $5- $7 billion of the approximately $25 billion spent on inhalers annually. The BreatheSuite System – composed of a disposable, battery-powered, portable BreatheSuite MDI add-on device and a mobile application based on behavior change strategies – is designed to work with an MDI by attaching to the top of the canister of the patient’s inhaler. The device and mobile app work together to evaluate and “score” a person’s inhaler technique and usage patterns, storing results in the cloud so the person can track and use this information to improve how they use their inhaler. With consent, this information can also be remotely monitored by the person’s healthcare team to promote customizable care plans. By promoting more effective inhaler use and remote patient monitoring (RPM), BreatheSuite aims to improve quality of care and health outcomes while reducing the economic burden associated with these conditions. Medical costs for chronic COPD were estimated to reach $49 billion in 2020, and the annual economic cost of asthma from 2008-2013 was more than $81.9 billion – with medical costs alone accounting for $50.3 billion. “We are extremely excited to have obtained FDA clearance, which is a critical step in achieving our vision of improving the lives of respiratory patients worldwide,” said Brett Vokey, Founder and CEO of BreatheSuite. “The COVID-19 pandemic has underscored that now is the time for remote patient monitoring to take a front seat in providing better, more transparent care for all people with asthma or COPD. With FDA clearance, we are poised to become a leader in providing actionable insights to people with asthma or COPD across the United States.” “By having a real-time way to digitally monitor and provide feedback to patients, we hope to enhance healthcare outcomes,” said Dr. Meshari F. Alwashmi, Chief Scientific Officer, BreatheSuite. “Furthermore, having an objective measure of adherence and technique from each user with asthma and COPD will advance the sphere of knowledge regarding the effectiveness of inhaled medications.” The BreatheSuite device does not interfere with regular MDI usage and can be removed and reattached to a new inhaler with ease. The device is compatible with 90% of MDIs on the market, including those manufactured by GlaxoSmithKline (GSK), Teva and Prasco. In addition to FDA clearance, which is a first for a Newfoundland and Labrador-based company, the BreatheSuite device has also been cleared for sale in Canada. About BreatheSuite BreatheSuite is a Canadian connected health company founded in 2018 to help people with chronic respiratory conditions live longer, healthier lives. The BreatheSuite MDI device is designed to track and train proper inhaler usage, while the BreatheSuite App applies behavior change tactics to improve adherence, and tips on how to improve inhaler technique. BreatheSuite works with leading partners across North America to deliver better care to people with chronic respiratory conditions. For more information visit www.breathesuite.com or contact info@BreatheSuite.com. Contact Details SVM Public Relations and Marketing Communications Jordan Bouclin +1 401-490-9700 jordan.bouclin@svmpr.com Company Website https://www.breathesuite.com/

September 28, 2021 10:00 AM Eastern Daylight Time

Image

R2 Technologies’ Novel Glacial Rx® System Earns Third FDA Indication and Unique Product Code

R2 Technologies

R2 Technologies Inc. ("R2"), the leader in CryoAesthetic™ medical devices, announces that its revolutionary in-office system, Glacial Rx®, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation, is now the first and only dermal cooling system FDA-cleared for general dermabrasion, scar and acne scar revision, and tattoo removal, permanently changing the aesthetics industry. “This additional FDA clearance is a huge win, and not an easy feat. It took innovation, dedication, time, and resources,” says Tim Holt, R2 Chief Executive Officer. “It couldn’t have been possible without our amazing team and strategic partners. The clearance had an exceptional outcome in which we went from being part of one classification, among hundreds of other devices, to being placed in our very own FDA-issued product code. This is further proof that our product is so novel, it warrants a completely new category.” “R2 has been at the forefront of the med-esthetics space since inception with its unmatched technology and continues to lead advancements in the industry. We are excited to see the company break boundaries yet again with its latest indication,” says David Present, MD and Cherine Eldumiati Plumaker, R2’s Chairman and Vice Chairman respectively. In conjunction with the commercial launch, R2 looked within its remarkable team of industry veterans, including the inventors of the Glacial Rx technology, Rox Anderson, MD; Dieter Manstein MD, PhD; and Henry Chan, MD, PhD, to create its newly established Scientific Advisory Board. By continuing to have these highly regarded pioneers as an integral part of the company, R2 stands out amongst the competitive medical aesthetics market as an industry frontrunner. “With the appointment of our new Scientific Advisory Board, R2 is tapping into years of knowledge and expertise to launch new groundbreaking innovations, develop a superior product pipeline, and leverage technical insights to secure new clinical indications and expansion opportunities,” says Holt. Launched in March 2021, Glacial Rx’s presence in the U.S. has grown significantly. R2 is continuing to take orders from aesthetic providers who want to offer this revolutionary treatment in-office. To learn more about R2, treatment offerings and providers, visit glacialskin.com and follow the company on LinkedIn. About R2 Technologies Headquartered in Silicon Valley, with a recent expansion in Florida and new Miami-based satellite office, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital and Blossom Innovations. In 2019, R2 brought on strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientiﬁc founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Its first innovation, Glacial Rx, was named one of the ‘2021 Launches Doctors are Buzzing About’ by RealSelf, the leading, most trusted source to educate on cosmetic procedures. R2 also won the 2nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital, and mentorship available to tech startups. Since inception, R2 has raised $76M in ﬁnancing. Contact Details Linsey Tilbor Rubin +1 732-991-5294 ltilbor@rellmc.com Company Website https://glacialskin.com/

September 28, 2021 08:33 AM Eastern Daylight Time

D8.co to Launch 1-Hour Delivery for Delta-8 THC Products

D8 Holdings, Inc.

D8.co the market leader in hemp-derived Delta-8 THC —today announced it is launching 1-hour delivery for consumer orders throughout the United States. D8.co will deliver their award winning Delta-8 carts, Delta-8 disposables, and Delta-8 gummies to any customer within 1-hour in a 25-mile radius of any professional NFL team. Outside that radius customers will receive next day packages at the latest. “The largest problem we have is fulfillment and delivery,” said Chris Duffield, CEO of D8.co. “Anyone shipping consumer goods knows that all the carriers are a current nightmare. We have shipped thousands of packages priority and the majority show up two or three days late, with far too many getting lost or stolen. If a customer places an order after cutoff on Friday, they have to wait an additional three days. Customers want our products, and they want them immediately.” The first six states D8.co will integrate into their program are Texas, Georgia, Florida, Minnesota, Ohio, and North Carolina. The company will expand into the rest of the U.S immediately, with full integration expected to take approximately 45 days. “We have more than 50 major fulfillment centers locked in that are centrally managed from our cloud technology. Once an order is placed, our customers will receive an email and text where they can track our drivers all the way to delivery,” said Hugh McPherson, EVP of D8.co. D8.co expects to immediately double online sales with the new integration. “We are extremely excited to launch 1-hour delivery,” said Duffield. “We just became the largest cannabis company in the United States, which makes us a prime acquisition target. I’m very proud of our core team and all the hard work everyone has put in to make D8 the number one brand in the market.” About D8.co D8.co is based in Colorado and Miami with satellite offices in Las Vegas and Los Angeles. The company is an assembly of the top hemp and cannabis minds in the country. With backgrounds in extraction, chemistry, manufacturing, marketing, distribution, and legal, the D8 team came together organically around this elusive, but extremely powerful molecule to create a new category of products. More info at www.d8.co. Contact Details D8.co Chris Duffield +1 424-333-2112 chris@d8.co Company Website https://d8.co/

September 23, 2021 12:26 PM Eastern Daylight Time

Prostate Cancer Racial Disparities

YourUpdateTV

Despite great strides in prostate cancer care over the past several years, racial disparities in care persist. Black and Hispanic men have a high burden of prostate cancer mortality. Prostate cancer affects 1 in 8 men, with the number rising to 1 in 6 for Black men and comprises more than 1 in 5 of all new cancer diagnoses for Hispanic men. The Covid-19 pandemic has also made things worse as early in the pandemic, many cancer resources were diverted, leaving scores of patients, including those with prostate cancer, with limited to no access to surgical treatment. So, what can be done and what does someone need to know to stay healthy? Conducting a nationwide media tour to discuss this important topic was Dr. Brian K. McNeil. Dr McNeil is an American Urological Association spokesperson and Associate Dean for Clinical Affairs, Vice-Chair, Department of Urology at SUNY Downstate Health Sciences University Topics that Dr McNeil discussed during interviews with radio and TV stations across the country included: What research has discovered about racial disparities among men with prostate cancer The racial disparity in the utilization of new therapies for advanced prostate cancer How covid-19 and where someone lives could affect their treatment options When should men get screened for prostate cancer? For more information visit: UrologyHealth.org About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 21, 2021 05:00 PM Eastern Daylight Time

CORRECTING and REPLACING: AS&K Group Sets Science Based Targets for Emissions Reduction

AS&K Group

This release issued on July 27, 2021 is being replaced with the following version due to updated hyperlinks. Medical communications group AS&K has set ambitious emissions reduction goals using the Science Based Target initiative’s (SBTi) framework for SMEs. This global organization provides companies with a clearly defined pathway to future-proof growth by specifying how much and how quickly they need to reduce their greenhouse gas (GHG) emissions. By joining more than 1,000 visionary businesses from all industries including major pharmaceutical companies, AS&K is leading the way in the medical communication sector in this important worldwide effort to tackle the climate crisis. AS&K has set a group-wide goal of 50% reduction in GHG emissions, which is in line with the most stringent goal of the Paris Agreement to keep global warming to 1.5C and prevent the most damaging effects of climate change. “AS&K understands the urgent need for companies to take action to address the climate crisis. We’re absolutely committed to doing all that we can, and will also work with our clients to reduce the climate impact of their medical communication activities,” said Simon Gee, AS&K Agency Head. As well as reducing emissions, AS&K is aiming to become net zero before 2030 by supporting programs that mitigate the effects of their remaining emissions. “The climate crisis is one of the most important issues of our times and we’re passionate about taking meaningful steps to reduce our carbon footprint. Joining the SBTi and setting emissions reduction goals is a critical first step in getting to net-zero as soon as we can,” added Katherine Vik, Senior Digital Project Manager and Chair of AS&K’s Climate Committee. “We are also running a number of workstreams to help our clients reduce the environmental impact of their medical communications.” More information about AS&K’s commitment is available on the SBTi website. About AS&K Group: The AS&K Group is an independently owned group of medical communications agencies who collaborate with leading pharmaceutical and medical device companies. As strategic partners and subject matter experts, the AS&K Group transforms complex scientific information into compelling programs that inform and educate healthcare professionals. The AS&K Group comprises three innovative companies: Remedica, AS&K Communications and The Corpus. Follow our journey on Twitter @asandkgroup and Linkedin Contact Details Alana Zdinak +44 7766 706656 alana.zdinak@asandk.com Company Website https://asandkgroup.com/

September 21, 2021 09:18 AM Eastern Daylight Time

1 ... 163 164 165 166 167 ... 201